Asthma is a pulmonary disorder characterized by reversible airflow obstruction, chronic airway inflammation, airways hyperresponsiveness (AHR), and remodeling. Asthma affects nearly 10% of the US population and is increasing in prevalence, making it a major public health problem. 1 Asthma is a complex and heterogeneous syndrome with a number of different clinical phenotypes associated with distinct cellular and molecular mechanisms 2 controlled by innate and adaptive immune responses to allergens, which rely on both immune cells (eg, dendritic cells [DCs] , T H 2 cells, T H 17 cells, and innate lymphoid cells) and structural cells, including airway epithelium. 3, 4 The exact biochemical processes underlying the diverse phenotypes of asthma and the precise contributions of lung structural and immune cells during asthma pathogenesis remain incompletely understood.
Changes in cellular metabolism, notably increases in glycolysis, accompany inflammatory responses. 5 Glucose is taken up by cells through glucose transporters and subsequently undergoes glycolysis through a stepwise cascade to form pyruvate, which can enter the mitochondria and undergo oxidative phosphorylation. Alternatively, pyruvate can be metabolized to lactate through lactate dehydrogenase A (LDHA). Aerobic glycolysis, the metabolism of glucose to form lactate in the presence of oxygen, is a feature of tumor or metabolically active cells and is associated with increased glucose uptake and lactate overproduction. 6, 7 Aerobic glycolysis also generates NADPH, which is important in protection against oxidative stress and preserves the carbon backbone of glucose to fuel macromolecule synthesis. 6, 7 Glucose metabolism is implicated in immune activation, and increases in glycolysis regulate immune effector function through multiple mechanisms. 8 For example, enhanced glycolysis has been shown to facilitate the polarization, activation, or both of immune cells. 9 Moreover, lactate, the end product of glycolysis, accumulates at the sites of chronic inflammation 10, 11 and tumor microenvironments, 12 which is indicative of increased glycolytic flux. However, virtually nothing is known about the glycolytic status in the setting of and the relevance of deregulated glycolysis in the pathogenesis of allergic airways diseases. A previous study demonstrated increases in lactate content in serum of asthmatic patients compared with that in patients with chronic obstructive pulmonary disease or healthy control subjects and increases in lactate levels in proliferating CD4 T cells isolated from asthmatic patients compared with levels in healthy subjects. The same authors demonstrated that intraperitoneal injection of dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase, attenuated increases in lactate levels in proliferating CD4 T cells and attenuated ragweed-induced allergic airways inflammation and AHR in mice. 13 However, the extent of increases in glycolysis in the airways of asthmatic patients remain unknown. Similarly, the signals that promote increases in glycolysis in allergically inflamed lung tissue also remain elusive. It is also not clear whether increases in glycolysis occur in lung epithelial cells and affect the response of epithelial cells to house dust mite (HDM) allergen.
Therefore the goal of the current study was to address some of these questions by using a mouse model of HDM-induced allergic airways disease, nasal epithelial cells (NECs), and sputum samples derived from asthmatic patients. Our results demonstrate that increases in glycolysis are a critical feature of allergic airways disease controlled by an IL-1/inhibitory kB kinase (IKK) ε signaling axis.
METHODS

Subjects' characteristics
The study population was enrolled at the asthma clinic in CHU Liege (Belgium). Healthy subjects were recruited at the hospital and the University of Liege, Liege, Belgium. The study cohort consisted of healthy subjects (n 5 20) and patients with asthma (n 5 94). The demographic and functional characteristics of the 114 subjects from the study cohort are shown in Table E1 in this article's Online Repository at www.jacionline.org. The study was approved by the local ethics committee of the University of Liege, Liege, Belgium (reference 2005/181; conforming to the Declaration of Helsinki).
NECs were isolated from healthy subjects (n 5 6) or patients with allergic rhinitis and asthma (n 5 7) enrolled at the University of Vermont Medical Center. Patients' characteristics are provided in Table E2 in this article's Online Repository at www.jacionline.org. The local institutional review board granted approval for all of the procedures involving human subjects (CHRMS 15-067). Additional details are provided in the Methods section in this article's Online Repository at www.jacionline.org.
Mouse studies
Age-matched 8-to 12-week-old mice were used (Jackson Laboratory, Bar Harbor, Me) for all experiments. Wild-type (WT; C57BL6/NJ), Rag 
Cell studies
Human NECs were isolated from healthy subjects or asthmatic patients. Cells were cultured and exposed to HDM for assessment of glycolysis proteins and lactate content in culture supernatants. Mouse tracheal epithelial (MTE) cells were isolated from tracheas of WT mice of mice or mice lacking Ikbke. Cells were cultured and exposed to the indicated mediators for assessment of lactate in supernatants, glucose uptake, extracellular acidification rate (ECAR), and cytokine levels in medium.
Statistical analysis
All data were evaluated with JMP Pro 10 (SAS Institute, Cary, NC) and GraphPad Prism 6 (GraphPad Software, La Jolla, Calif) software. Cell-culture and mouse data were compared with either 1-way or 2-way ANOVA, followed by a Tukey post hoc test. Scoring of histologic staining was analyzed by using the Kruskal-Wallis test. Human demographic data were compared by using the Student t test, x 2 test, or Wilcoxon rank sum test. Human sputum data for lactate and IL-1b were log-transformed before being compared with the Student t test. Comparisons of sputum data between asthmatic and healthy participants were adjusted for differences in body mass index (BMI) by using analysis of covariance. P values of less than .05 were considered statistically significant.
More detailed information on the materials and methods used in this study is available in the Methods section in this article's Online Repository.
RESULTS
Increases in glycolysis in lungs from mice with HDM-induced allergic airways disease
Low pH is a characteristic of chronic inflammatory sites 10, 14, 15 and results mainly from a metabolic shift to aerobic glycolysis and subsequent lactate overproduction. Little is known about the glycolytic status in asthmatic patients. Therefore we first determined whether glycolysis was affected in an HDM model of allergic airways disease (Fig 1, A) . No increases in lactate levels were observed acutely after HDM (days 1 and 2; Fig 1, B) . Five consecutive daily exposures to HDM in week 3 without prior sensitization during weeks 1 and 2 (day 20: 2Xsaline and 5XHDM) also did not result in increases in lactate levels (Fig 1, B) . However, lactate levels were increased in the bronchoalveolar lavage (BAL) fluid and lung tissue homogenates of mice at day 20 after 2 sensitizations and 5 challenges (Fig 1, B) . Significant increases in lactate production were also observed 24 hours (day 30) after HDM rechallenge on day 29 in mice previously sensitized and challenged with HDM (2XHDM, 5XHDM, and HDM). These increases in lactate levels on days 20 and 30 corresponded with increases in total cell counts and, notably, increases in neutrophil counts in BAL fluid (see Fig E1 in this article's Online Repository at www.jacionline.org) 16 and suggest that increases in lactate levels are a feature of the adaptive immune response.
Increased expression of glycolysis proteins, including hexokinase 1, hexokinase 2 (HK2), and LDHA, were observed in lung tissue homogenates 20 or 29 days after HDM exposure, whereas they tended to decrease at day 30 (Fig 1, C) . LDHA preferentially converts pyruvate to lactate. 17 Immunohistochemical analysis of LDHA in saline-exposed mouse lung tissues revealed that LDHA was constitutively expressed in bronchial epithelial and alveolar type II cells (Fig 1, D) . In response to HDM sensitization and challenge, widespread increases in LDHA expression were apparent in lung tissue, with increases in immunoreactivity present not only in cells resembling infiltrating immune cells, which is consistent with the previously appreciated role of glycolysis in immune effector function, 9 but also in bronchial epithelial cells (Fig 1, D) . These findings suggest that both structural and hematopoietic cells might be responsible for HDM-mediated increases in lactate production.
An adaptive immune response and IL-1 signaling are required for increases in glycolysis in lungs of mice with HDM-induced allergic airways disease To elucidate the mediators that cause glycolysis, we evaluated a number of proinflammatory mediators and assessed whether their levels correlated with increases in lactate levels. Levels of IL-1b, IL-6, and TNF-a, but not IL-1a and IL-17, were increased at times that roughly corresponded to increases in lactate levels (Fig 2, A) .
Next, we sought to determine whether IL-1 signaling plays a causal role in augmentation of glycolysis in patients with HDM-induced disease. Neutralization of IL-1 with IL-1 Trap (Regeneron Pharmaceuticals, Tarrytown, NY; see Fig E2 in this article's Online Repository at www.jacionline.org) 18 attenuated HDM-mediated lactate increases (Fig 2, B) , as well as expression of the glycolytic enzymes HK2 and LDHA (Fig 2, C) , demonstrating the functional importance of IL-1 in augmenting glycolysis in HDM-exposed mice.
The delayed increases in lactate levels in BAL fluid and lung tissues after HDM sensitization and challenge suggest the requirement of an adaptive immune response. To directly test whether IL-1-dependent increases in glycolysis in response to HDM were dependent on adaptive immunity, we assessed lactate levels in HDM-exposed WT and Rag1 Saline/HDM  rechallenge   0  3  y  a  D  9  2  y  a  D  0  2  y  a  D  2  y  a  D  1 
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which lack mature B and T lymphocytes. 19 Previously, we published that Rag1 2/2 mice exhibited robust decreases in HDM-induced immune cell influx in BAL fluid and IgG and IgE production. 20 Strikingly, the HDM-mediated increases in lactate (Fig 2, D) and IL-1b (Fig 2, E) levels were completely inhibited in Rag 2/2 mice. Taken together, our results suggest that HDM-induced adaptive immunity is required for IL-1 signaling and resultant increases in glycolysis.
To address whether IL-1b is sufficient to increase glycolysis, we administered IL-1b directly into the airways of WT mice. IL-1b caused increases in lactate levels in BAL fluid at 6 and 24 hours after administration and in lung tissue 48 hours after administration and resulted in increases in BAL fluid neutrophil counts, along with increases in levels of the proinflammatory cytokines CCL20, chemokine (C-X-C) motif ligand 1 (KC), GM-CSF, and thymic stromal lymphopoietin (TSLP) in lung tissue (see Fig E3 in this article' s Online Repository at www.jacionline.org). Increases in lactate levels were accompanied by increases in HK2 and LDHA levels in lung tissue (Fig 2, G) . Evaluation of LDHA by means of immunohistochemistry revealed increases in LDHA levels in bronchial epithelia 24 hours after administration of IL-1b (Fig 2, H) .
Increased glycolysis promotes IL-1a-and IL-1b-mediated proinflammatory responses in airway epithelial cells and augments release of proinflammatory mediators after subsequent exposure to HDM Our findings demonstrating that intranasal administration of IL1b increases BAL lactate levels 6 hours later, a time point before recruitment of inflammatory cells (see Fig E3, B and C), suggest that IL-1b increases glycolysis in airway epithelial cells in settings of allergic airways disease. To directly address this possibility, we exposed MTE cells to IL-1b or IL-1a for 24 hours. Both cytokines resulted in a significant increase in lactate levels in culture supernatants. No increases in lactate levels were observed 24 hours after exposure to IL-6, IL-13, IL-33, TGF-b1, TNFa, IL-17, LPS, or HDM (Fig 3, A) , demonstrating notable selectivity of IL-1a/b in augmenting glycolysis in MTE cells in these experimental settings. Concomitant to increases in lactate levels, IL-1b significantly augmented expression of a number of genes in the glycolysis pathway (Fig 3, B) . IL-1b-treated MTE cells had higher basal ECARs than vehicle-exposed cells, indicating a higher rate of release of lactate levels into the culture medium. In response to glucose injection, IL-1b-treated cells demonstrated a higher ECAR compared with control cells. IL-1b-treated cells were also more sensitive to the ATP synthesis inhibitor oligomycin and maintained a higher ECAR (Fig 3, C) , revealing the higher glycolytic capacity of IL-1b-treated cells. Addition of 2-deoxyglucose (2-DG), a competitive inhibitor of glucose hexokinase, decreased ECAR to baseline levels, confirming that the observed ECAR is due to glycolysis (Fig 3, C) . In contrast to changes in ECAR, oxygen consumption rates were similar in control and IL-1b-treated cells (Fig 3, C) . In line with these observations, glucose levels in the medium decreased and glucose uptake was increased in response to IL-1b (Fig 3, D) . These findings collectively demonstrate IL-1b (and IL-1a) to be an inducer of glycolysis in lung epithelial cells and that the ability of IL-1 to augment glycolysis in these experimental settings is not shared by other asthma-relevant mediators tested herein.
The importance of glycolysis in regulating immune effector function responses is well established. 21, 22 It is not known whether glycolysis regulates proinflammatory responses in epithelial cells exposed to IL-1b. Therefore we inhibited glycolysis by pretreating MTE cells with the hexokinase inhibitor 2-DG or the LDHA inhibitor oxamate and assessed IL-1b-induced proinflammatory cytokine levels. As shown in Fig 4, A, 2-DG completely blocked IL-1b-induced lactate production and strongly attenuated production of TSLP, GM-CSF, KC, and CCL20 in response to IL-1b (Fig 4, B) . Similar inhibitory effects on IL-1b-induced lactate and proinflammatory cytokine levels were observed in cells treated with oxamate (Fig 4, C and D) . 2-DG and oxamate did not induce cell death (see Fig E4, A, in this article's Online Repository at www.jacionline.org), demonstrating that decreases in cytokine levels observed are not due to a loss of survival. Similar to IL-1b, IL-1a also resulted in increases in the same cytokines, which were also inhibited by 2-DG or oxamate (see Fig E4, B) , suggesting that both interleukins trigger similar glycolysis-dependent proinflammatory responses in epithelial cells.
Results in Fig 2, F and H, demonstrate that IL-1b was sufficient to increase lactate levels in lung tissues and expression of LDHA in bronchial epithelia. Next, we tested whether IL-1b-mediated increases in glycolysis in epithelial cells affected their subsequent response to HDM to gain insights into the functional effect of enhanced glycolysis (which would be expected to occur in a setting in which IL-1 levels are increased) for subsequent responses to allergens in airway epithelia. We treated MTE cells with 2-DG for 1 hour or oxamate overnight, followed by treatment with IL-1b for 24 hours. Cells were then washed and exposed to HDM for 2 hours (Fig 4, E and F) . Although IL-1b or HDM individually led to increases in levels of proinflammatory cytokines, a strong synergy was observed in cells sequentially exposed to IL-1b and HDM. Importantly, inhibition of glycolysis with 2-DG strongly attenuated the IL-1b plus HDM-induced levels in TSLP or GM-CSF and moderately decreased CCL20 and KC levels (Fig 4,  E) . Similar responses were observed with oxamate (Fig 4, F) , with the exception of KC, which remained unaffected. Collectively, these data demonstrate that IL-1b-induced glycolysis augments the subsequent proinflammatory responses of epithelial cells to HDM. The IKK family includes 4 kinase members, the canonical IKKa and IKKb and 2 noncanonical family members, IKKε and TANK-binding kinase 1 (TBK1). Previously, we showed that activation of IKKb plays a critical role in the pathogenesis of allergic airways disease. 23, 24 Essentially no information exists about the role of other IKKs. IKKε is emerging as a critical regulator of T H 17 maintenance, IL-17-induced airway neutrophilia, 25 and glycolytic reprogramming in DCs. 21 Therefore we explored whether IKKε levels were increased during the pathogenesis of HDM-induced allergic airways disease and whether IKKε contributed to IL-1b-induced glycolysis. In mice with HDMinduced disease, expression of IKKa and IKKb increased in lung tissues (Fig 5, A) , which is consistent with our previous observations. 16, 26 We also observed robust and prolonged increases in IKKε and TBK1 levels in lung tissues (Fig 5, A) .
Next, we addressed the effect of Ikbke ablation (the gene encoding IKKε; Fig 5, B) on HDM-induced glycolysis and allergic airways disease. Ablation of Ikbke significantly attenuated the HDM-mediated increases in lactate levels (Fig 5. C), suggesting a requirement for Ikbke in HDM-induced glycolysis. Assessment of HDM-induced airway inflammation revealed slight decreases in overall BAL fluid cell counts in HDM-challenged Ikbke 2/2 mice compared with those in their WT littermates, as reflected by slight but nonsignificant decreases in neutrophil counts, significant decreases in eosinophil counts, and a lack of differences in macrophage or lymphocyte counts (Fig 5, D) .
Similar to our previous studies, 16 significant increases in airway resistance (Rn) occurred in HDM-challenged WT mice compared with control mice (Fig 5, E) . Although HDM-exposed Ikbke 2/2 mice showed comparable increases in baseline Rn compared with saline-exposed mice, no further increases in Rn in response to increasing doses of methacholine were observed. No differences in tissue resistance were observed between any of the groups. Converse to the attenuation of HDM-mediated increased in Rn observed in HDM-exposed Ikbke 2/2 mice, tissue elastance was significantly increased (Fig 5, E) , suggesting complex modulation of AHR in mice lacking Ikbke.
In WT mice HDM led to mucus metaplasia and increases in Muc5AC levels in BAL fluid (Fig 5, F and G) in association with increases in IL-33 and IL-13 levels in lung tissues (Fig 5, H) , which is consistent with a type 2, eosinophil-associated inflammatory response. In contrast, HDM-mediated increases in mucus metaplasia, Muc5AC, IL-33, IL-13, and CCL20 levels were strongly attenuated in Ikbke 2/2 mice (Fig 5, F-H ), suggesting that absence of Ikbke attenuates type 2 inflammation. Although TSLP levels were constitutively lower in Ikbke 2/2 mice compared with their WT counterparts, no effect of HDM was observed at this time point (Fig 5, H) . No differences between HDM-mediated increases in IL-1b levels were observed between WT or Ikbke 2/2 mice (Fig 5, H) , suggesting that IL-1b levels are increased proximally to or independently of Ikbke.
Because of these findings, attenuation of HDM-induced lactate levels in lung tissues from Ikbke 2/2 mice compared with WT littermates (Fig 5, C) , and the previously reported role of IKKε in glycolytic reprogramming of DCs, 21 we next addressed the role of Ikbke in IL-1b-mediated increases in glycolysis in lung tissue. IL-1b administration was sufficient to increase lactate levels in WT mice. The IL-1b-mediated increases in lactate levels were almost completely abolished in Ikbke 2/2 mice (Fig 5, I ), suggesting that Ikbke is required for IL-1b-induced glycolysis.
Strong increases in IKKε immunolocalization were observed in bronchial epithelial cells in response to HDM or IL-1b (Fig 6, A) . Therefore we explored the effect of IL-1b on IKKε expression and the role of IKKε in IL-1b-induced glycolysis. Exposure of MTE cells to IL-1b was sufficient to upregulate Ikbke mRNA (Fig 6, B) . IL-1b-mediated increases in lactate levels were attenuated in Ikbke 2/2 MTE cells (Fig 6, C) . Similarly, the IKKε/TBK1 inhibitor amlexanox resulted in a dose-dependent decrease in IL-1b-induced lactate in MTE cells (Fig 6, D) and abrogated IL-1b-mediated increases in Glut1, Hk2, Ldha, and Pkm2 mRNA (Fig 6, E) . The more potent effects of amlexanox compared with Ikbke ablation are potentially caused by amlexanox targeting both IKKε and TBK1. 27 Next, we addressed the effect of IKKε/TBK1 on the IL-1b-mediated augmentation of HDM-induced proinflammatory responses. WT cells were treated with amlexanox overnight, followed by treatment with IL-1b for 24 hours. Cells were then washed and exposed to HDM for 2 hours (Fig 6, F) . Similar to results in Fig 4 , E, prior exposure to IL-1b led to augmentation of HDM-induced release of proinflammatory mediators from MTE cells (Fig 6, F) . Amlexanox ablated the IL-1b plus HDM-mediated increases in TSLP and GM-CSF levels and attenuated CCL20 and KC (Fig 6, F) , which was identical to our findings with 2-DG (Fig 4, E) . Comparative evaluation of WT and Ikbke 2/2 epithelial cells demonstrated a strong attenuation of IL-1b/HDM-mediated increases of TSLP and a modest attenuation of KC and GM-CSF, whereas CCL20 levels were increased equally in Ikbke 2/2 and WT cells in response to IL-1b/HDM (Fig 6, G) . Overall, these data suggest that IKKε is FIG 2. HDM-induced T-and B-cell adaptive immune responses are required for IL-1b production and resultant increases in glycolysis in lung tissue. A, Levels of proinflammatory cytokines in lung tissue of HDM-exposed mice at the times indicated. *P < .05 compared with saline groups (ANOVA; n 5 5 per group). B and C, Lactate levels in BAL fluid and homogenized lung tissue (Fig 2, B) and Western blot analysis of HK2 and LDHA in lung tissue (Fig 2, C) from saline-or HDM-exposed mice treated with vehicle (Veh) or IL-1 Trap. Mice were harvested at day 20. *P < .05 compared with the saline group and P < .05 compared with the HDM/Veh group (ANOVA; n 5 5 per group). D and E, Lactate levels in BAL fluid and lung tissue (Fig 2, D) and IL-1b levels in lung tissue (Fig 2, E) from Rag 2/2 and WT mice exposed to saline or HDM. Mice were analyzed at day 20. *P < .05 compared with the saline controls and P < .05 compared with the respective WT group (ANOVA, n 5 4-8 per group). F, Lactate levels in BAL fluid and lung tissue from the mice 6, 24, 48, and 72 hours after intranasal administration of IL-1b. *P < .05 compared with vehicle-exposed mice (ANOVA, n 5 5-8 per group). G, a critical mediator in IL-1b-induced glycolysis and subsequent augmentation of HDM-mediated increases in TSLP levels in airway epithelial cells and that the further decreases in CCL20, GM-CSF, and KC levels observed in response to amlexanox in these settings (Fig 6, F) might be attributable to TBK1.
LDHA augments lactate levels in lung tissue and contributes to HDM-induced allergic airways disease
To address the functional importance of increased glycolysis, we administered Ldha small interfering RNA (siRNA) in mice Glucose consumption Glucose uptake with pre-existing allergic airways disease (Fig 7, A) .
SiRNA-mediated ablation of Ldha attenuated HDM-mediated increases in LDHA expression (Fig 7, B) and lactate levels (Fig 7, C) and markedly decreased HDM-mediated increases in airway inflammation (Fig 7, D) . Ldha siRNA attenuated tissue levels of IL-33, IL-13, and CCL20 but did not affect GM-CSF, IL-1b, or TSLP (Fig 7, E) . Ldha siRNA decreased HDM-induced mucus metaplasia and diminished Muc5AC levels in BAL fluid in HDM-exposed mice (Fig 7, F and G) , which is consistent with diminished type 2 inflammatory responses. Although siRNA-mediated ablation of Ldha did not affect Rn, it attenuated tissue resistance and elastance compared with control siRNA HDM-exposed mice (Fig 7, H) . Collectively, these findings point to the functional relevance of LDHA-linked glycolysis in HDM-induced airways disease and that increases in glycolysis are an important proinflammatory signal. (Fig 4, A  and C) and levels of proinflammatory mediators (Fig 4, B and D) in cell-culture supernatants of MTE cells. MTE cells were pretreated with 2-DG (10 mmol/L; Fig 4, A and B) or oxamate (10 mmol/L; Fig 4, C and D) , followed by stimulation with IL-1b (10 ng/mL) for 24 hours. E and F, Importance of glycolysis in IL-1b-mediated augmentation of HDM (50 mg/mL)-induced KC, CCL20, TSLP, and GM-CSF levels in culture supernatants. *P < .05 compared with the non-HDM-exposed sham group, P < .05 compared with the respective non-IL-1b-treated vehicle group (Veh), and àP < .05 relative to non-2-DGor non-oxamate-treated control group (Ctrl; 2-way ANOVA).
Evidence for increased glycolysis in asthmatic patients in association with airway neutrophil counts
To address the relevance of these findings for human asthma, we evaluated increases in glycolysis proteins and lactate levels in primary NECs. Protein levels of LDHA and pyruvate kinase M2 were constitutively increased in NECs from asthmatic patients compared with those in control subjects (Fig 8, A , and see Fig E5, A, in this article's Online Repository at www.jacionline.org) in association with increases in lactate levels (Fig 8, B) . In response to HDM, no further differences in expression of these mediators were observed. These findings suggest that NECs from asthmatic patients show an intrinsic increase in glycolysis. Assessment of cell-free sputum samples of healthy subjects (n 5 20) or asthmatic patients (n 5 94) showed increased lactate levels in asthmatic patients compared with control subjects (Fig 8, C) . Sputum lactate levels negatively correlated with percentage FEV 1 in asthmatic patients but not in healthy subjects (Fig 8, D) . Although overall levels of IL-1b in sputum samples were not significantly higher in the overall asthmatic population than in control subjects (Fig 8, E) , a significant correlation was apparent between lactate and IL-1b levels in asthmatic patients (Fig 8, F) .
Given the large fluctuations in lactate (range, 5.3-362.9 mmol/L) and IL-1b (range, 0.8-262.8 pg/mL) levels in asthmatic patients, we investigated further whether these parameters were related to specific clinical features. Lactate or IL-1b levels were not increased in patients with eosinophilic asthma (>3% sputum eosinophils) compared with those in patients with low eosinophil counts (< _3% eosinophils; P 5 .81 and .57, respectively). Lactate levels were not different between atopic and nonatopic asthmatic patients (P 5 .67). IL-1b levels trended toward being increased in atopic compared with nonatopic asthmatic patients (P 5 .07). Lactate and IL-1b levels trended toward increases in asthmatic patients who received corticosteroids compared with those in patients who did not (P 5 .09 and .07, respectively). Lactate and IL-1b levels were significantly increased in patients with neutrophilic asthma (>61% sputum neutrophils; see Fig E5, B) compared with those in patients with 61% or less neutrophils. Lactate levels (but not IL-1b levels) were significantly greater in patients whose asthma was uncontrolled (see Fig E5, B) .
BMI was increased in asthmatic patients compared with healthy subjects (see Table E1 ). Adjustment for BMI still showed significant increases in lactate levels in asthmatic patients compared with healthy subjects (P 5 .0002). Collectively, these data suggest that IL-1-linked glycolysis is an important feature of allergic asthma.
DISCUSSION
Perturbations in glycolysis are implicated in the pathogenesis of several chronic inflammatory diseases. 10, 28 However, the role of dysregulated glycolysis in patients with allergic asthma is not well appreciated. Herein we discovered that in mice with HDM-induced allergic airways disease, glycolysis was increased in association with HDM-induced inflammation, mucus metaplasia, and AHR. Our results also illuminated that IL-1-and IKKε-dependent signals are important in augmenting glycolysis in HDM-exposed mice and in enhancing HDM-induced proinflammatory signals in epithelial cells. Importantly, inhibition of glycolysis through administration of Ldha siRNA in mice with pre-existing allergic airways disease attenuated the pathophysiologic manifestations of allergic airways disease. These findings have potential relevance to human asthma given the robust increases in expression of LDHA and increased levels of lactate in primary human NECs and cell-culture supernatants, respectively, and the observed positive correlation between lactate and IL-1b levels in sputum samples from patients with asthma.
In the present study we demonstrated the importance of IL-1 signaling in mediating HDM-induced glycolysis. This claim is based on findings demonstrating that increases in IL-1b levels were temporally correlated with increases in lactate levels in response to HDM, that neutralization of IL-1 significantly attenuated HDM-induced glycolysis, and that administration of IL-1b into the airways or MTE cells was sufficient to increase glycolysis. These findings are consistent with earlier studies showing that IL-1 signaling increases glycolysis during T H 17 cell differentiation 29 and in mesangial cells. 30 IL-1a and IL-1b share biological activity by acting exclusively on IL-1 receptor type I (IL-1RI), 31 and various studies suggest that both cytokines play critical roles in asthmatic patients. [32] [33] [34] [35] [36] [37] Neutralizing IL-1a during allergic sensitization to HDM resulted in strongly attenuated T H 2 inflammation. 36 Although we did not detect increases in IL-1a levels at times that corresponded with increases in lactate levels, we cannot rule out the possibility that IL-1a might be involved in increased glycolysis in settings of allergic airways disease. Because IL-1b and IL-1a both activate IL-1RI and increase glycolysis in epithelial cells (Fig 3) and IL-1 Trap decreased both IL-1b and IL-1a levels in lung tissue (see Fig E2) , their relative contributions in mediating HDM-induced glycolysis need to be further dissected. Lastly, we also report that HDM-induced adaptive immunity is required for the observed increases in IL-1b levels and associated increases in lactate levels.
FIG 5.
A causal role for IKKε in HDM-and IL-1b-mediated increases in glycolysis and the pathogenesis of allergic airways diseases. A, Western blot analyses of IKKs in lung tissues of WT mice subjected to the HDM regimen for the indicated times. WT or Ikbke 2/2 mice were exposed as described in Fig 1. B-E, Mice were killed at day 20 for assessment of IKKε in lung tissue through Western blot analysis (Fig 5, B) , lactate levels in lung tissues (Fig 5, C) , total and differential cell counts in BAL fluid (Fig 5, D) , and AHR (Fig 5, E) . *P < .05 compared with the saline control group and P < .05 compared with respective WT mice (ANOVA, n 5 5-10 per group). F, Assessment of mucus metaplasia in WT or Ikbke 2/2 mice exposed to HDM or saline (scale bar 5 50 mm; top). Quantification of airway mucus staining (periodic acid-Schiff) intensity (bottom). Data are expressed as means 6 SEMs from 5 mice per group. *P < .05 compared with respective saline controls and P < .05 compared with WT HDM groups (Kruskal-Wallis test). G and H, Levels of Muc5AC (Fig 5, G) and proinflammatory mediators (Fig 5, H) in lung tissues of WT and Ikbke 2/2 mice exposed to HDM, as described in Fig 5, B to E. I, BAL fluid and lung lactate levels in WT and Ikbke 2/2 mice exposed to IL-1b for 24 hours. *P < .05 relative to vehicle (Veh) control group and P < .05 relative to the respective WT group (ANOVA, n 5 5-10 per group). IL-1b for 24 h. *P < .05 compared with sham controls and P < .05 relative to respective WT (ANOVA). D, Lactate levels in cell-culture supernatants of MTE cells treated with vehicle or amlexanox at the indicated concentrations. EOS, Eosinophils; LYM, lymphocytes; MAC, macrophages. *P < .05 compared with sham controls (Student t test). E, Attenuation of IL-1b-induced expression of glycolysis genes in MTE cells pretreated with 100 mmol/L amlexanox. MCh, Methacholine. *P < .05 relative to the vehicle/sham group and P < .05 relative to vehicle/IL-1b (ANOVA). F, MTE cells were pretreated with 100 mmol/L amlexanox followed by stimulation with IL-1b for 24 hours before exposure to HDM (50 mg/mL) for an additional 2 hours, according to the indicated schematic. KC, CCL20, TSLP, and GM-CSF levels in cell-culture supernatants of MTE cells. G, KC, CCL20, TSLP, and GM-CSF levels in supernatants of WT or Ikbke 2/2 MTE cells sequentially exposed to IL-1b and HDM according to the schematic. *P < .05 relative to the non-HDM-exposed sham group, P < .05 compared with the respective non-IL-1b-treated vehicle group (Veh), and àP < .05 relative to respective non-amlexanox-treated control group (Fig 6, F) or WT group (Fig 6, G; 2-way ANOVA). , and Ldha siRNAs. B-E, At day 40, saline-or HDM-exposed mice treated with control siRNA or Ldha siRNA were harvested for assessment of LDHA protein levels in lung tissue through Western blot analyses (Fig 7, B) , lactate levels in BAL fluid and lung tissue (Fig 7, C) , total and differential cell counts in BAL fluid (Fig 7,  D) , and IL-1b, CCL20, IL-33, TSLP, GM-CSF, and IL-13 levels in lung tissue (Fig 7, E) . EOS, Eosinophils; LYM, lymphocytes; MAC, macrophages. *P < .05 relative to the naive group and P < .05 relative to the HDM/control siRNA group (ANOVA). F, Periodic acid-Schiff staining of airway mucus in saline-or HDM-exposed mice treated with control or Ldha siRNA (scale bar 5 50 mm; left). Quantification of airway mucus staining (periodic acid-Schiff) intensity is shown at right. Data are expressed as means 6 SEMs from 5 to 6 mice per group. *P < .05 compared with naive mice and P < .05 compared with the HDM/control siRNA group (Kruskal-Wallis test) . G, Measurement of Muc5AC levels in BAL fluid from mice described in Fig 7, A-E. H, Assessment of AHR. MCh, Methacholine. *P < .05 relative to naive group and P < .05 relative to the HDM/control siRNA group (ANOVA). Data are representative of 6 healthy subjects and 6 asthmatic patients. B, Lactate content in culture supernatants of cells shown in Fig 8, A. *P < .05 compared with cells from healthy control subjects not exposed to HDM and P < .05 compared with cells from healthy control subjects exposed to HDM (ANOVA). C-F, Lactate (Fig 8, C) and IL-1b (Fig 8, E ) levels in sputum supernatants from healthy subjects (n 5 20) or asthmatic patients (n 5 94). Correlations between lactate content and FEV 1 percent predicted (Fig 8, D) or IL-1b levels (Fig 8, F) in asthmatic patients and healthy subjects arre shown. Correlation analyses were performed by using Spearman rank correlation coefficients.
IL-1β HDM
h 2 h MTECs
Alterations in cellular metabolism are known to affect immune cell function, 9 and increases in glycolysis have been shown to regulate immune effector function. 21, 22, [38] [39] [40] [41] Despite these studies, the role of enhanced glycolysis in structural cells, such as airway epithelium, and implications for their innate effector function has remained unknown. Here we demonstrate that inhibition of glycolysis through targeting hexokinase or LDHA markedly dampened IL-1a-or IL-1b-induced proinflammatory responses and strongly attenuated the ability of IL-1b to augment HDM-induced innate cytokine responses in MTE cells.
Overall, these findings suggest that enhanced glycolysis is important for the amplification of allergen-induced proinflammatory responses. However, further mechanistic studies will be required to unravel how glycolysis modulates proinflammatory responses in epithelial cells. Rapid ATP generation during glycolysis is required for immediate energy demand during immune cell proliferation and activation. 9 We and others have shown that extracellular ATP activates purinergic receptors, leading to release of IL-33 from epithelial cells, 42 suggesting a potential mechanism whereby increased glycolysis augments epithelial effector function.
In the present study we also demonstrate that IKKε expression is increased in bronchial epithelium in response to HDM or IL-1b and that it promotes glycolysis and proinflammatory responses in epithelial cells and contributes to HDM-induced allergic airways disease. However, the molecular details whereby IL-1 and IKKε enhance glycolysis remain unknown. IL-1 has been shown recently to activate IKKε and the subsequent AKT-mammalian target of rapamycin (mTOR) signaling pathway, leading to T H 17 cell maintenance, 25 and AKT or mTOR, when activated, are known to induce glycolysis, 21, 43 suggesting the potential role of AKT-mTOR signaling in HDM/IL-1/IKKε-induced glycolysis.
The connection of IL-1 signaling and glycolysis described herein in the murine model of allergic airway disease is corroborated by our findings in samples from asthmatic patients. As was mentioned above, lactate levels were significantly greater in sputum samples of asthmatic patients. Furthermore, lactate and IL-1b levels were positively correlated in sputum supernatants from asthmatic patients, and lactate levels negatively correlated with lung function. Lactate and IL-1b levels were notably increased in patients with neutrophilic asthma (> _61% neutrophils), whereas no correlations between these parameters and eosinophil counts were observed.
IL-1b has been implicated in a number of pulmonary diseases. [44] [45] [46] Although increases in IL-1b observed herein are not specific to only patients with asthma, IL-1b is emerging as a key cytokine relevant to the pathogenesis of asthma. 47 IL-1b has been linked to severe, neutrophilic, steroid-insensitive asthma in a mouse model. 48 In contrast to the present data, a recent study suggested a critical role for the IL-1b pathway in patients with T H 2/T H 17-predominant asthma (having 4% of BAL fluid neutrophils), whereas IL-1a was linked to neutrophilic asthma (having 16% BAL neutrophils). 49 The discrepancy between these findings can be associated with differences in patients' characteristics and sampling (sputum compared with BAL fluid analyses) and illuminates the complexities among the various asthma subtypes. Therefore additional studies will be essential to unravel the contributions of IL-1a and IL-1b and activation of glycolysis pathways in the asthma subtypes.
Excessive b-agonist administration has been associated with increased plasma lactate levels. [50] [51] [52] We believe it is unlikely that salbutamol used to induce sputum in our study contributed to the increased level of sputum lactate because a low dose of salbutamol (400 mg) was used, and both healthy subjects and asthmatic patients received salbutamol. This notion is also backed by our findings that NECs from asthmatic patients expressed more LDHA and produced more lactate compared with control subjects in the absence of exposure to b-agonists (Fig 8) . The latter findings also suggest that human NECs from asthmatic patients are intrinsically different from their counterparts derived from healthy subjects. Considering that IL-1 proteins can be produced by epithelial cells, 36 it will be interesting to elucidate whether epithelial IL-1 and IL-1RI signaling form an autocrine loop that sustains the constitutive overproduction of lactate observed in NECs derived from asthmatic patients. Furthermore, an epigenetic mechanism can also be involved in this process because a recent study discovered that, during T H 1 cell differentiation, LDHA-mediated increases in glycolysis maintain a high concentration of acetyl coenzyme A that in turn enhances histone acetylation. 53 In summary, the present study demonstrates the importance of glycolysis in the pathophysiology of allergic airways disease and suggests that targeting glycolysis 6,54,55 might ultimately provide a new approach in the treatment of asthma. Additional studies will be required to elucidate the cell types in which enhanced glycolysis occurs in asthma settings. Similarly, the molecular details by which changes in glycolysis regulate the effector function of epithelial cells and other cell types also warrant further investigation.
Key messages
d Primary NECs from asthmatic patients intrinsically express more LDHA and produce more lactate compared with those from healthy control subjects, and sputum lactate levels negatively correlate with lung function in asthmatic patients.
d The IL-1/IKKε signaling axis mediates HDM-induced glycolysis and allergic airways disease in mice.
d Increases in glycolysis are critical in the augmentation of HDM-triggered proinflammatory responses in airway epithelial cells.
METHODS
Sputum induction
Sputum was induced and processed, as described previously.
E1-E3
Before sputum induction, subjects inhaled 400 mg of salbutamol through a metered-dose inhaler (plus spacer). Sputum was induced with an ultrasonic nebulizer (Ultra-Neb 2000, Devilbiss, Somerset, Pa; output set at 0.9 mL/min). Subjects inhaled hypertonic saline (NaCl 5%) when FEV 1 after salbutamol was 65% of predicted value or greater and isotonic saline (NaCl 0.9%) when FEV 1 was less than 65% of predicted value. The aerosol was inhaled for 3 consecutive periods of 5 minutes. FEV 1 was monitored every 5 minutes for safety reasons, and when FEV 1 decreased to 80% of postbronchodilator values, the induction procedure was stopped.
Whole sputum was weighed, and 3 volumes of PBS were added. After homogenizing by means of manual agitation for 30 seconds and centrifugation (800g) for 10 minutes at 48C, the cell pellet and supernatant were separated. Cells were treated with Sputolysin 0.1% (Calbiochem, Darmstadt, Germany), washed with PBS, and resuspended in 1 mL. Total cell counts, percentage of squamous cells, and cell viability (trypan blue staining) were determined with a manual hemocytometer. Sputum cell differentials were determined by counting 500 nonsquamous cells on cytospin samples stained with RAPI-DIFF II stain (Atom Scientific, Manchester, United Kingdom).
Cell culture and treatments
Primary human NECs were isolated from 6 healthy volunteers and 6 patients with allergic rhinitis and asthma by means of gentle stroking of the inferior turbinate surface with a Rhino-Probe curette and cultured, as recently described, E4 in bronchial epithelial cell growth medium (Lonza, Basel, Switzerland). Atopy was confirmed by using positive skin test responses and increased serum IgE levels (>100 IU/mL). Asthma was diagnosed by physicians and confirmed by a positive response to bronchodilator (> _200 mL and 12% improvement in FEV 1 , forced vital capacity, or both) or a positive methacholine challenge test result (PC 20 < 8 mg/mL), and rhinitis was determined based on a sinonasal questionnaire score E5 of greater than 1. Healthy volunteers had no history of rhinitis or asthma, negative skin test results, negative methacholine challenge test results, and a sinonasal questionnaire score of less than 1.
For experiments, NECs were plated on collagen-coated 12-well plates at a density of 2 3 10 5 cells/well and cultured in a 1:1 mixture of bronchial epithelial cell basic medium and DMEM-H with SingleQuot supplements (Cambrex, East Rutherford, NJ), bovine pituitary extract (13 mg/mL), BSA (1.5 mg/mL), and nystatin (20 units). After 2 hours of starvation in basal medium, NECs were treated with 50 mg/mL HDM (Dermatophagoides pteronyssinus; Greer Laboratories, Lenoir, NC; 144.9 endotoxin units/mg protein; lot 290903) for 24 hours. Primary MTE cells were isolated from WT C57BL/6 mice or C57BL/6 mice lacking the IKKε gene (referred to herein as Ikbke 2/2 ) and cultured, as previously described. E6,E7 After reaching confluence, MTE cells were incubated for 16 hours in serum-free medium. Cells were stimulated with IL-1a (10 ng/mL), IL-1b (10 ng/mL), IL-6 (10 ng/mL), IL-13 (5 ng/mL), IL-33 (5 ng/mL), TGF-b1 (5 ng/mL), TNF-a (5 ng/mL), IL-17 (20 ng/mL), LPS (1 mg/mL), or HDM (10 mg/mL or 50 mg/mL, as indicated in the figure legend) for 2 or 24 hours.
Cells were pretreated with the hexokinase inhibitor 2-DG (10 mmol/L) for 1 hour before exposure to IL-1b for 24 hours to address the importance of glycolysis or IKKε/TBK1 in IL-1b-induced proinflammatory responses in MTE cells. Alternatively, cells were incubated with the LDHA inhibitor oxamate (10 mmol/L) or the IKKε/TBK1 inhibitor amlexanox (10-100 mmol/L; Tocris Bioscience, Bristol, United Kingdom) overnight, followed by stimulation with IL-1b (10 ng/mL) for 24 hours. To determine whether IL-1b-induced glycolysis or IKKε/TBK1 augmented the subsequent response to HDM, in select experiments cells were washed after inhibitor/IL-1b treatment, incubated with DMEM/F12 medium for 2 hours before stimulation with HDM for an additional 2 hours according to the schematic illustrations shown in the relevant figures. MTE cells were preincubated with 10 mmol/L 2-DG for 1 hour or 10 mmol/L oxamate for 16 hours before exposure to IL-1a for 24 hours and subsequent assessment of proinflammatory mediators in supernatants to address the role of glycolysis in IL-1a-dependent proinflammatory responses. Note that absolute values of KC vary between studies because of freezing of some supernatants. E8 In select experiments 1 mg of IL-1b (R&D Systems, Minneapolis, Minn; resuspended in 0.1% BSA in PBS) was administered directly through the intranasal route.
Mouse studies
Assessment of AHR
After completion of the HDM protocol, mice were anesthetized with intraperitoneal pentobarbital sodium (90 mg/kg), tracheotomized, and ventilated mechanically at 200 breaths/min. Mice were subjected to increasing doses of methacholine (0, 12.5, 25, 50, and 100 mg/mL) administered by means of ultrasonic nebulization, and respiratory mechanics were assessed by using a forced oscillation technique on a computer-controlled small-animal ventilator (SCIREQ, Montreal, Quebec, Canada), as previously described.
E9,E10 Parameters of Newtonian resistance (Rn), tissue resistance, and elastance were calculated and quantified by averaging the 3 highest measurements obtained at each incremental methacholine dose for each mouse.
E9,E10
Assessment of mucus metaplasia
Airway mucus was stained with periodic acid-Schiff, and the staining intensity was evaluated by means of slide scoring by 2 independent blinded investigators.
E11 MUC5AC levels were evaluated in lung tissue or BAL fluid by means of ELISA (MyBioSource, San Diego, Calif).
BAL fluid processing
After mice were killed, BAL was performed with 1 mL of PBS. BAL fluid was collected, and total cell counts were determined with an ADVIA 120 Automated Hematology Analyzer (Siemens Healthcare, Malvern, Pa). BAL fluid was spun down at 1200g for 5 minutes. Cells were transferred to slides by using a cytospin device, fixed in methanol, stained with the Hema3 kit (Fisher Scientific, Kalamazoo, Mich) and analyzed by counting a minimum of 300 cells per mouse, as described elsewhere. E11 Supernatants were flash frozen in liquid nitrogen and stored at 2808C until analysis.
ELISA
IL-1a, IL-1b, IL-6, TNF-a, IL-17, GM-CSF, and CCL20 were detected by means of ELISA in lung homogenates (normalized for protein) or supernatants from cell culture, according to the manufacturer's instructions (R&D Systems).
Quantitative RT-PCR
RNA was extracted by using miRNeasy columns (Qiagen, Valencia, Calif), as directed by the manufacturer. One microgram of RNA was reverse transcribed to cDNA for gene analysis by using SYBR Green (Bio-Rad Laboratories, Hercules, Calif) to assess expression of monocarboxylate transporter 4 (Mct4); phosphofructokinase, live type (Pfkl); hexokinase 2 (Hk2); glucose transporter 1 (Glut1); glucose transporter 3 (Glut3); pyruvate kinase isoenzyme type M2 (Pkm2); lactate dehydrogenase A (Ldha); phosphoglucomutase 1 (Pgm1); pyruvate dehydrogenase kinase 1 (Pdk1); triosephosphate isomerase 1 (Tpi1); enolase 1 (Eno1); phosphoglycerate kinase 1 (Pgk1); glucose-6-phosphate isomerase (Gpi); 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (Pfkfb3); monocarboxylate transporter 1 (Mct1); glucose transporter 2 (Glut2); and IKKε (Ikbke). Expression values were normalized to the housekeeping gene cyclophilin. Detailed primer sequences are provided in Table E3 . The plate was incubated in a 378C non-CO 2 incubator for 1 hour. The plate was then transferred to the Seahorse XF24 Analyzer for analysis and subjected to ECAR measurements, followed by successive treatments with glucose (10 mmol/L), oligomycin (0.25 mmol/L), and 2-DG (100 mmol/L).
Glucose measurements
Glucose consumption and uptake in MTE cells were measured 24 hours after stimulation with IL-1b by measuring glucose concentrations in cellculture supernatants (Eton Bioscience, San Diego, Calif) and cellular incorporation of fluorescent glucose analog (2-NBDG, 2-[N-[7-Nitrobenz-2-oxa-1,3-diazol-4-yl]Amino]-2-Deoxyglucose; Life Technologies, Grand Island, NY) by using a plate reader (Biotek, Winooski, Vt).
Immunohistochemistry
Fixed sections were prepared for immunostaining by deparaffinizing with xylene and rehydrating through a series of ethanols. For antigen retrieval, slides were heated for 20 minutes in 958C citrate buffer (pH 6.0) and then rinsed in distilled water. Sections were then blocked for 1 hour in blocking serum, according to the manufacturer's instructions (Vectastain Alkaline Phosphatase Universal; Vector Laboratories, Burlingame, Calif). Slides were then washed in TBS with 0.1% TWEEN-20 335 min, followed by incubation with primary antibody for LDHA overnight at 48C. Sections were washed again and incubated with a biotinylated universal secondary antibody (Vectastain Alkaline Phosphatase Universal, Vector Laboratories) for 30 minutes at room temperature. Slides were washed and incubated with the Vectastain ABC-AP reagent (prepared as per manufacturer's instructions) for 30 minutes at room temperature. Sections were then incubated with Vector Red/Vector Blue Alkaline Phosphatase Substrate Kit I (Vector Laboratories) for 10 minutes at room temperature, rinsed with tap water, and counterstained with Mayer hematoxylin.
Immunofluorescence
After death, left lobes were fixed with 4% paraformaldehyde, stored at 48C overnight for fixation of the tissue, and mounted in paraffin, and 5-mm sections were affixed to glass microscope slides for histopathology, as previously described. E12 For antigen retrieval, slides were heated for 20 minutes in 958C citrate buffer (pH 6.0) with 0.05% Tween 20 and then rinsed in distilled water. Sections were then blocked for 1 hour in 1% BSA in PBS, followed by incubation with primary antibody for IKBKE (Cell Signaling Technology, Danvers, Mass) at 1:100 overnight at 48C. Slides were then washed for 335 minutes in PBS, incubated with Alexa Fluor 647, and counterstained with 49-6-diamidino-2-phenylindole dihydrochloride in PBS for nuclear localization. Sections were imaged with a Zeiss 510-META confocal laser scanning microscope (Zeiss, Oberkochen, Germany).
Lactate assay
Lactate concentrations in medium, BAL fluid, and lung homogenates were assessed with a Lactate Assay Kit (Eton Bioscience), according to the manufacturer's recommendations. A, Lung tissue levels of KC, TSLP, CCL20, and GM-CSF after intranasal administration of IL-1b or vehicle. B and C, Total (Fig E3, B) and differential (Fig E3, C) cell counts in BAL fluid from mice at multiple time points after intranasal administration of vehicle or IL-1b. Data are expressed as means 6 SEMs (n 5 5 mice per group). EOS, Eosinophils; LYM, lymphocytes; MAC, macrophages; NEU, neutrophils. *P < .05 (ANOVA) compared with vehicle controls (Veh). 
